The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised


About Bioabsorbable Therapeutics

Bioabsorbable Therapeutics (BTI) was founded to develop the next generation of devices for treating vascular disease. BTI uses novel, proprietary polymers and fabrication technologies to create fully bioabsorbable stents. The lead product is a fully bioabsorbable coronary stent called the IDEAL Stent.On October 22, 2010, Bioabsorbable Therapeutics was acquired by MultiCell Technologies. The terms of the transaction were not disclosed.

Bioabsorbable Therapeutics Headquarter Location

959 Hamilton Avenue

Menlo Park, California, 94025,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Bioabsorbable Therapeutics Patents

Bioabsorbable Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Surgical removal procedures, Biomaterials, Surgical oncology, Implants (medicine), Polymers


Application Date


Grant Date



Related Topics

Surgical removal procedures, Biomaterials, Surgical oncology, Implants (medicine), Polymers



Latest Bioabsorbable Therapeutics News

Global Cardiovascular Stent Market (2021 to 2026) - Featuring Abbott, Medtronic and Boston Scientific Among Others -

Nov 11, 2021

Bioabsorbable Therapeutics Inc. A cardiovascular stent is used in the re-opening of a blocked or narrowed coronary artery. These stents are also used in improving the blood flow in the heart. It also reduces the risk of heart attack or heat stroke and hence improving the person's life. The prime reason driving the market growth during the forecasted period is rising cases of cardiovascular diseases, which has raised serious concerns. Furthermore, a rising proportion of the geriatric population has increased the chances of artery failure, which requires the implementation of cardiovascular stents for smoother blood flow. However, chances of developing blood clots around the area of stent create a problem for the patient and hence create a limitation for the market growth. furthermore, substitute medical treatments are available which also hinders the market size. Rising cases of cardiovascular diseases are predicted to increase the demand for cardiovascular stents. Cardiovascular diseases increase the chances of developing blockages in an artery in a patient, and hence the threat to life. rising cases of cardiovascular diseases are expected to drive the demand for cardiovascular stents during the forecasted period. Data from World Health Organization shows that cardiovascular diseases are the leading cause of death worldwide, accounting for 32% of deaths annually. It is calculated by the organization that roughly around 17.9 million people die because of cardiovascular diseases. In the United States, data from the Centre for Disease Control cites that 655,000 Americans die every year due to heart problems. The growing geriatric population having cardiovascular diseases is expected to increase the adoption of the cardiovascular stent, and hence drive the market growth during the study period. One of the prime users of cardiovascular stents is the aged population having cardiovascular diseases who require the support of stents for easy blood flow in the body. it is anticipated that an increasing proportion of the aged population in the overall demography will drive the market growth of the cardiovascular stent industry. Data from World Bank Database shows that the population aged 65 and above increased to 9.5% of global demography in 2020. The United Nations estimates that this proportion will further increase to around 15% by the end of 2050. The increased geriatric population, hence, is expected to drive in a significant market. The risk of developing clot and substitute medical treatment has the potential to constrain the market growth of the cardiovascular stent industry during the forecasted period. One of the prime constraints that are faced by cardiovascular stent technology is the risk of developing a blood clot after surgery that continues to disturb blood flow in the body. Research has found that about 1% to 2% of the patients who get a cardiovascular stent implemented in their body have the chance of developing blood clots around the stent. This blood clot disturbs the blood flow by the heart and puts the patients at serious risk of heart attack or stroke. The risk of developing a blood clot is higher in the initial months after the implementation of the stent. However, risk prevails forever and develops despite taking several measures during and after the insertion medical procedure. COVID-19 Insights The coronavirus pandemic reduced the size of the cardiovascular stent market, impacting the industry negatively. A fall in demand for cardiovascular stents was observed due to reducing routine check-ups resulting in a reduction in the location of patients with artery blockage. Key Topics Covered:

  • When was Bioabsorbable Therapeutics founded?

    Bioabsorbable Therapeutics was founded in 2004.

  • Where is Bioabsorbable Therapeutics's headquarters?

    Bioabsorbable Therapeutics's headquarters is located at 959 Hamilton Avenue, Menlo Park.

  • What is Bioabsorbable Therapeutics's latest funding round?

    Bioabsorbable Therapeutics's latest funding round is Acquired.

  • How much did Bioabsorbable Therapeutics raise?

    Bioabsorbable Therapeutics raised a total of $9M.

  • Who are the investors of Bioabsorbable Therapeutics?

    Investors of Bioabsorbable Therapeutics include MultiCell Technologies, Life Science Angels, BioStar Capital, Synergy Partners International, Finistere Ventures and 5 more.

  • Who are Bioabsorbable Therapeutics's competitors?

    Competitors of Bioabsorbable Therapeutics include Endologix, Microfabrica, TriVascular Technologies, Veryan Medical, TriReme Medical and 13 more.

You May Also Like

Devices for Vascular Intervention

Devices for Vascular Interventions offers atherectomy systems for removal of plaque from coronary arteries

Endologix Logo

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

Reva Medical

Founded in 1998, REVA Medical is dedicated to developing interventional medical devices that leverage the Company's stent designs and biomaterials to improve the treatment of vascular disease. nnThe Company's flagship product is a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then fade away, leaving only the healed vessel behind. This product promises to revolutionize the treatment of coronary artery disease. REVA Medical has a broad strategic relationship with Boston Scientific Corporation, a worldwide developer and marketer of interventional medical devices. The Company is also certified to the ISO 13485:2003 standard.

Veryan Medical Logo
Veryan Medical

Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan's BioMimics 3D stent technology involves adapting traditional straight stent designs to a patented three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology has been proven to enhance clinical performance by improving flow conditions in, and the biomechanical performance of, stented vessels. The advanced, biomimetic design of the BioMimics 3D stent is intended to provide improved flow conditions and more flexibility, kink and fracture resistance than other nitinol stents. Veryan's Research & Development facility is located in Galway, Ireland.

Micell Technologies

Micell Technologies aims to bring together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent.

TriReme Medical

TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.